• Explore /
  • Poster
  • / ProCAID: A phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone (DP) chemotherapy for metastatic castration resistant prostate cancer (mCRPC).

ProCAID: A phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone (DP) chemotherapy for metastatic castration resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Simon J. Crabb

Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom

Simon J. Crabb , Alison J. Birtle , Karen Martin , Nichola Downs , Megan Bowers , Ian Ratcliffe , Mary Ellis , Gareth Griffiths , Stuart Thompson , Vincent Khoo , Robert J. Jones

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02121639

Citation

J Clin Oncol 34, 2016 (suppl 2S; abstr 228)

DOI

10.1200/jco.2016.34.2_suppl.228

Abstract #

228

Poster Bd #

J21

Abstract Disclosures

Similar Posters

First Author: Tanya B. Dorff

First Author: Simon J. Crabb

First Author: Sarah Elizabeth Fenton

First Author: Benedito A. Carneiro